• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Systemic venous thrombosis after recombinant factor VIIa in the control of bleeding after cardiac surgery.心脏手术后使用重组凝血因子VIIa控制出血后发生的系统性静脉血栓形成。
Tex Heart Inst J. 2007;34(4):485-8.
2
Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.应用重组活化因子 VII 控制体外循环下心内直视手术后难治性出血
J Cardiothorac Vasc Anesth. 2011 Dec;25(6):987-94. doi: 10.1053/j.jvca.2011.05.012. Epub 2011 Aug 11.
3
Deep vein thrombosis after recombinant factor VIIa infusion to control severe recurrent postoperative bleeding.输注重组凝血因子VIIa控制严重复发性术后出血后发生的深静脉血栓形成。
Anesthesiology. 2006 Apr;104(4):892-3. doi: 10.1097/00000542-200604000-00043.
4
Was systemic venous thrombosis really due to the administration of recombinant factor VIIa? or was it possibly a manifestation of Lemierre syndrome?系统性静脉血栓形成真的是由于重组凝血因子VIIa的给药所致吗？还是它可能是勒米尔综合征的一种表现？
Tex Heart Inst J. 2008;35(3):373-4; author reply 374-6.
5
Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin.重组凝血因子VIIa用于心脏手术后因直接凝血酶抑制剂比伐卢定抗凝继发的难治性出血。
Pharmacotherapy. 2006 Apr;26(4):569-577. doi: 10.1592/phco.26.4.576.
6
Con: The role of recombinant factor VIIa in the control of bleeding after cardiac surgery.
J Cardiothorac Vasc Anesth. 2008 Oct;22(5):783-5. doi: 10.1053/j.jvca.2008.05.003.
7
[Recombinant activated factor VII for perioperative bleeding].
Rev Med Chil. 2009 Jun;137(6):837-43. Epub 2009 Sep 4.
8
Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis.重组凝血因子VIIa用于心脏手术后难治性失血：倾向评分匹配的病例对照分析
Transfusion. 2005 Jan;45(1):26-34. doi: 10.1111/j.1537-2995.2005.04216.x.
9
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery.在心脏手术后出血的非血友病患者中使用重组凝血因子VIIa的剂量
Am J Health Syst Pharm. 2007 Sep 1;64(17):1808-12. doi: 10.2146/ajhp060398.
10
Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.重组凝血因子VIIa（诺其）用于先天性心脏病手术后的止血剂。
Paediatr Anaesth. 2005 Mar;15(3):235-40. doi: 10.1111/j.1460-9592.2005.01429.x.

引用本文的文献

1
Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial.用于减少心脏手术中输血的凝血因子VIII抑制物旁路活性制剂（FEIBA）：一项随机、双盲、安慰剂对照的试点试验。
Pilot Feasibility Stud. 2021 Jul 2;7(1):137. doi: 10.1186/s40814-021-00873-5.
2
Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients.重组活化凝血因子VII在控制非血友病患者出血中的应用
Ann Saudi Med. 2010 May-Jun;30(3):198-202. doi: 10.4103/0256-4947.62830.
3
Spontaneous deep vein thrombosis in hemophilia A: a case report.甲型血友病患者自发性深静脉血栓形成：一例报告
Cases J. 2009 Sep 11;2:6390. doi: 10.1186/1757-1626-0002-0000006390.
4
Was systemic venous thrombosis really due to the administration of recombinant factor VIIa? or was it possibly a manifestation of Lemierre syndrome?系统性静脉血栓形成真的是由于重组凝血因子VIIa的给药所致吗？还是它可能是勒米尔综合征的一种表现？
Tex Heart Inst J. 2008;35(3):373-4; author reply 374-6.

本文引用的文献

1
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.使用重组人凝血因子VIIa后的血栓栓塞不良事件。
JAMA. 2006 Jan 18;295(3):293-8. doi: 10.1001/jama.295.3.293.
2
Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study.体外循环后活化重组因子VII减少复杂非冠状动脉心脏手术中的异体输血：随机双盲安慰剂对照试验研究
Br J Anaesth. 2005 Nov;95(5):596-602. doi: 10.1093/bja/aei244. Epub 2005 Sep 23.
3
Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.重组凝血因子VIIa作为严重创伤患者出血控制的辅助治疗：两项平行随机、安慰剂对照、双盲临床试验。
J Trauma. 2005 Jul;59(1):8-15; discussion 15-8. doi: 10.1097/01.ta.0000171453.37949.b7.
4
Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.重组凝血因子VIIa用于心脏手术后出血的治疗
Ann Thorac Surg. 2005 Jul;80(1):66-71. doi: 10.1016/j.athoracsur.2005.02.044.
5
Is recombinant FVIIa the magic bullet in the treatment of major bleeding?
Br J Anaesth. 2005 May;94(5):553-5. doi: 10.1093/bja/aei103.
6
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.活化重组凝血因子VII在骨盆或骨盆与髋臼创伤性骨折重建手术患者中的应用：一项双盲、随机、安慰剂对照试验。
Br J Anaesth. 2005 May;94(5):586-91. doi: 10.1093/bja/aei102. Epub 2005 Feb 25.
7
Recombinant activated factor VII for acute intracerebral hemorrhage.重组活化凝血因子 VII 用于急性脑出血
N Engl J Med. 2005 Feb 24;352(8):777-85. doi: 10.1056/NEJMoa042991.
8
Recombinant factor VIIa for life-threatening post-partum haemorrhage.重组凝血因子VIIa用于治疗危及生命的产后出血。
Br J Anaesth. 2005 May;94(5):592-5. doi: 10.1093/bja/aei094. Epub 2005 Feb 11.
9
Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.重组凝血因子VIIa用于肝大部切除术：一项随机、安慰剂对照、双盲临床试验
Anesthesiology. 2005 Feb;102(2):269-75. doi: 10.1097/00000542-200502000-00006.
10
Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis.重组凝血因子VIIa用于心脏手术后难治性失血：倾向评分匹配的病例对照分析
Transfusion. 2005 Jan;45(1):26-34. doi: 10.1111/j.1537-2995.2005.04216.x.

心脏手术后使用重组凝血因子VIIa控制出血后发生的系统性静脉血栓形成。

Systemic venous thrombosis after recombinant factor VIIa in the control of bleeding after cardiac surgery.

作者信息

Mahmoud Amr, Al-Ruzzeh Sharif, McKeague Helena, Cross Mike

机构信息

Leeds General Infirmary, Leeds LS1 3EX, United Kingdom.

出版信息

Tex Heart Inst J. 2007;34(4):485-8.

PMID:18172537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2170501/
Abstract

Recombinant factor VIIa has been licensed in the United Kingdom since 1996 for the control of bleeding in hemophilic patients who are actively bleeding or are about to undergo surgery. Medical practitioners are also applying recombinant factor VIIa toward the control of bleeding in patients without hemophilia. Although the efficacy of recombinant factor VIIa has been shown in many patients, concerns have arisen about the risk of thrombotic adverse events. Herein, we report the case of a 73-year-old woman who underwent major coronary surgery and developed fatal systemic venous thrombosis after recombinant factor VIIa was used in an attempt to control her severe postoperative bleeding. We review the medical literature and discuss the risks of using recombinant factor VIIa to control severe bleeding after cardiac surgery.

摘要

自1996年起，重组凝血因子VIIa在英国已获许可，用于控制正在出血或即将接受手术的血友病患者的出血情况。医学从业者也将重组凝血因子VIIa用于控制非血友病患者的出血。尽管重组凝血因子VIIa在许多患者中已显示出疗效，但人们对血栓形成不良事件的风险产生了担忧。在此，我们报告一例73岁女性患者的病例，该患者接受了重大冠状动脉手术，在使用重组凝血因子VIIa试图控制其严重的术后出血后，发生了致命的全身性静脉血栓形成。我们回顾了医学文献，并讨论了使用重组凝血因子VIIa控制心脏手术后严重出血的风险。